Table 1 Open in new tab Patient...

Variable	All patients (N = 80)	Non-severe MR (N = 51)	Dynamic severe MR (N = 12)	Severe MR at rest (N = 17)	P-value
Demographics
Sex female, n (%)	43 (53.8)	30 (58.8)	6 (50.0)	7 (41.2)	0.432
BMI (kg/m²)	25.5 (23.0–29.3)	27.0 (23.0–30.1)	23.9 (21.3–25.7)	26.2 (23.8–28.2)	0.134
Age (years)	80 (77–83)	80 (77–84)	81 (78–84)	80 (76–81)	0.748
Diabetes mellitus, n (%)	21 (26.6)	17 (34.0)	1 (8.3)	3 (17.7)	0.138
Hypertension, n (%)	71 (88.8)	46 (90.2)	10 (83.3)	15 (88.2)	0.793
Smoking, n (%)	12 (15.2)	8 (15.7)	1 (8.3)	3 (17.7)	0.767
CAD, n (%)	57 (71.3)	37 (72.6)	8 (66.7)	12 (70.6)	0.919
NYHA class					0.328
NYHA 1, n (%)	7 (8.8)	7 (13.7)	0 (0.0)	0 (0.0)
NYHA 2, n (%)	29 (36.3)	18 (35.3)	4 (33.3)	7 (41.2)
NYHA 3, n (%)	44 (55.0)	26 (51.0)	8 (66.7)	10 (58.8)
Atrial fibrillation, n (%)	80 (100.0)	51 (100.0)	12 (100.0)	17 (100.0)	>0.999
H₂FPEF score	6.0 (5.3–6.0)	6.0 (5.0–7.0)	6.0 (6.0–6.0)	6.0 (5.5–6.0)	0.595
H₂FPEF score ≥6 points	60 (75.0)	37 (72.5)	10 (83.3)	13 (76.5)	0.731
Medication
β-Blocker, n (%)	67 (85.9)	44 (86.3)	10 (83.3)	13 (76.5)	0.637
ACE-I/AT-1 blocker, n (%)	63 (78.8)	42 (82.4)	8 (66.7)	13 (76.5)	0.474
m antagonist, n (%)	15 (18.8)	8 (15.7)	2 (16.7)	5 (29.4)	0.446
Sacubitril/valsartan, n (%)	4 (5.0)	3 (5.9)	0 (0.0)	1 (6.3)	0.690
Diuretic, n (%)	72 (90.0)	47 (92.2)	10 (83.3)	15 (94.1)	0.242
Laboratory markers
Creatinine (mg/dL)	1.1 (0.9–1.5)	1.1 (0.9–1.6)	1.1 (0.9–1.4)	1.2 (0.9–1.7)	0.636
Haemoglobin (mg/dL)	12.7 (11.7–14.0)	12.4 (10.5–14.0)	13.0 (11.9–14.1)	12.6 (9.5–14.2)	0.497
NT-proBNP (ng/mL)	1756 (1034–3340)	1882 (994–3074)	1620 (1020–2608)	1768 (1175–3973)	0.638

Variable

All patients (N = 80)

Non-severe MR (N = 51)

Dynamic severe MR (N = 12)

Severe MR at rest (N = 17)

P-value

Demographics

Sex female, n (%)

43 (53.8)

30 (58.8)

6 (50.0)

7 (41.2)

0.432

BMI (kg/m²)

25.5 (23.0–29.3)

27.0 (23.0–30.1)

23.9 (21.3–25.7)

26.2 (23.8–28.2)

0.134

Age (years)

80 (77–83)

80 (77–84)

81 (78–84)

80 (76–81)

0.748

Diabetes mellitus, n (%)

21 (26.6)

17 (34.0)

1 (8.3)

3 (17.7)

0.138

Hypertension, n (%)

71 (88.8)

46 (90.2)

10 (83.3)

15 (88.2)

0.793

Smoking, n (%)

12 (15.2)

8 (15.7)

1 (8.3)

3 (17.7)

0.767

CAD, n (%)

57 (71.3)

37 (72.6)

8 (66.7)

12 (70.6)

0.919

NYHA class

0.328

NYHA 1, n (%)

7 (8.8)

7 (13.7)

0 (0.0)

NYHA 2, n (%)

29 (36.3)

18 (35.3)

4 (33.3)

7 (41.2)

NYHA 3, n (%)

44 (55.0)

26 (51.0)

8 (66.7)

10 (58.8)

Atrial fibrillation, n (%)

80 (100.0)

51 (100.0)

12 (100.0)

17 (100.0)

>0.999

H₂FPEF score

6.0 (5.3–6.0)

6.0 (5.0–7.0)

6.0 (6.0–6.0)

6.0 (5.5–6.0)

0.595

H₂FPEF score ≥6 points

60 (75.0)

37 (72.5)

10 (83.3)

13 (76.5)

0.731

Medication

β-Blocker, n (%)

67 (85.9)

44 (86.3)

10 (83.3)

13 (76.5)

0.637

ACE-I/AT-1 blocker, n (%)

63 (78.8)

42 (82.4)

8 (66.7)

13 (76.5)

0.474

m antagonist, n (%)

15 (18.8)

8 (15.7)

2 (16.7)

5 (29.4)

0.446

Sacubitril/valsartan, n (%)

4 (5.0)

3 (5.9)

0 (0.0)

1 (6.3)

0.690

Diuretic, n (%)

72 (90.0)

47 (92.2)

10 (83.3)

15 (94.1)

0.242

Laboratory markers

Creatinine (mg/dL)

1.1 (0.9–1.5)

1.1 (0.9–1.6)

1.1 (0.9–1.4)

1.2 (0.9–1.7)

0.636

Haemoglobin (mg/dL)

12.7 (11.7–14.0)

12.4 (10.5–14.0)

13.0 (11.9–14.1)

12.6 (9.5–14.2)

0.497

NT-proBNP (ng/mL)

1756 (1034–3340)

1882 (994–3074)

1620 (1020–2608)

1768 (1175–3973)

0.638

Variable	All patients (N = 80)	Non-severe MR (N = 51)	Dynamic severe MR (N = 12)	Severe MR at rest (N = 17)	P-value
Demographics
Sex female, n (%)	43 (53.8)	30 (58.8)	6 (50.0)	7 (41.2)	0.432
BMI (kg/m²)	25.5 (23.0–29.3)	27.0 (23.0–30.1)	23.9 (21.3–25.7)	26.2 (23.8–28.2)	0.134
Age (years)	80 (77–83)	80 (77–84)	81 (78–84)	80 (76–81)	0.748
Diabetes mellitus, n (%)	21 (26.6)	17 (34.0)	1 (8.3)	3 (17.7)	0.138
Hypertension, n (%)	71 (88.8)	46 (90.2)	10 (83.3)	15 (88.2)	0.793
Smoking, n (%)	12 (15.2)	8 (15.7)	1 (8.3)	3 (17.7)	0.767
CAD, n (%)	57 (71.3)	37 (72.6)	8 (66.7)	12 (70.6)	0.919
NYHA class					0.328
NYHA 1, n (%)	7 (8.8)	7 (13.7)	0 (0.0)	0 (0.0)
NYHA 2, n (%)	29 (36.3)	18 (35.3)	4 (33.3)	7 (41.2)
NYHA 3, n (%)	44 (55.0)	26 (51.0)	8 (66.7)	10 (58.8)
Atrial fibrillation, n (%)	80 (100.0)	51 (100.0)	12 (100.0)	17 (100.0)	>0.999
H₂FPEF score	6.0 (5.3–6.0)	6.0 (5.0–7.0)	6.0 (6.0–6.0)	6.0 (5.5–6.0)	0.595
H₂FPEF score ≥6 points	60 (75.0)	37 (72.5)	10 (83.3)	13 (76.5)	0.731
Medication
β-Blocker, n (%)	67 (85.9)	44 (86.3)	10 (83.3)	13 (76.5)	0.637
ACE-I/AT-1 blocker, n (%)	63 (78.8)	42 (82.4)	8 (66.7)	13 (76.5)	0.474
m antagonist, n (%)	15 (18.8)	8 (15.7)	2 (16.7)	5 (29.4)	0.446
Sacubitril/valsartan, n (%)	4 (5.0)	3 (5.9)	0 (0.0)	1 (6.3)	0.690
Diuretic, n (%)	72 (90.0)	47 (92.2)	10 (83.3)	15 (94.1)	0.242
Laboratory markers
Creatinine (mg/dL)	1.1 (0.9–1.5)	1.1 (0.9–1.6)	1.1 (0.9–1.4)	1.2 (0.9–1.7)	0.636
Haemoglobin (mg/dL)	12.7 (11.7–14.0)	12.4 (10.5–14.0)	13.0 (11.9–14.1)	12.6 (9.5–14.2)	0.497
NT-proBNP (ng/mL)	1756 (1034–3340)	1882 (994–3074)	1620 (1020–2608)	1768 (1175–3973)	0.638

Table 1

Open in new tab

Patient characteristics

Variable	All patients (N = 80)	Non-severe MR (N = 51)	Dynamic severe MR (N = 12)	Severe MR at rest (N = 17)	P-value
Demographics
Sex female, n (%)	43 (53.8)	30 (58.8)	6 (50.0)	7 (41.2)	0.432
BMI (kg/m²)	25.5 (23.0–29.3)	27.0 (23.0–30.1)	23.9 (21.3–25.7)	26.2 (23.8–28.2)	0.134
Age (years)	80 (77–83)	80 (77–84)	81 (78–84)	80 (76–81)	0.748
Diabetes mellitus, n (%)	21 (26.6)	17 (34.0)	1 (8.3)	3 (17.7)	0.138
Hypertension, n (%)	71 (88.8)	46 (90.2)	10 (83.3)	15 (88.2)	0.793
Smoking, n (%)	12 (15.2)	8 (15.7)	1 (8.3)	3 (17.7)	0.767
CAD, n (%)	57 (71.3)	37 (72.6)	8 (66.7)	12 (70.6)	0.919
NYHA class					0.328
NYHA 1, n (%)	7 (8.8)	7 (13.7)	0 (0.0)	0 (0.0)
NYHA 2, n (%)	29 (36.3)	18 (35.3)	4 (33.3)	7 (41.2)
NYHA 3, n (%)	44 (55.0)	26 (51.0)	8 (66.7)	10 (58.8)
Atrial fibrillation, n (%)	80 (100.0)	51 (100.0)	12 (100.0)	17 (100.0)	>0.999
H₂FPEF score	6.0 (5.3–6.0)	6.0 (5.0–7.0)	6.0 (6.0–6.0)	6.0 (5.5–6.0)	0.595
H₂FPEF score ≥6 points	60 (75.0)	37 (72.5)	10 (83.3)	13 (76.5)	0.731
Medication
β-Blocker, n (%)	67 (85.9)	44 (86.3)	10 (83.3)	13 (76.5)	0.637
ACE-I/AT-1 blocker, n (%)	63 (78.8)	42 (82.4)	8 (66.7)	13 (76.5)	0.474
m antagonist, n (%)	15 (18.8)	8 (15.7)	2 (16.7)	5 (29.4)	0.446
Sacubitril/valsartan, n (%)	4 (5.0)	3 (5.9)	0 (0.0)	1 (6.3)	0.690
Diuretic, n (%)	72 (90.0)	47 (92.2)	10 (83.3)	15 (94.1)	0.242
Laboratory markers
Creatinine (mg/dL)	1.1 (0.9–1.5)	1.1 (0.9–1.6)	1.1 (0.9–1.4)	1.2 (0.9–1.7)	0.636
Haemoglobin (mg/dL)	12.7 (11.7–14.0)	12.4 (10.5–14.0)	13.0 (11.9–14.1)	12.6 (9.5–14.2)	0.497
NT-proBNP (ng/mL)	1756 (1034–3340)	1882 (994–3074)	1620 (1020–2608)	1768 (1175–3973)	0.638

Variable	All patients (N = 80)	Non-severe MR (N = 51)	Dynamic severe MR (N = 12)	Severe MR at rest (N = 17)	P-value
Demographics
Sex female, n (%)	43 (53.8)	30 (58.8)	6 (50.0)	7 (41.2)	0.432
BMI (kg/m²)	25.5 (23.0–29.3)	27.0 (23.0–30.1)	23.9 (21.3–25.7)	26.2 (23.8–28.2)	0.134
Age (years)	80 (77–83)	80 (77–84)	81 (78–84)	80 (76–81)	0.748
Diabetes mellitus, n (%)	21 (26.6)	17 (34.0)	1 (8.3)	3 (17.7)	0.138
Hypertension, n (%)	71 (88.8)	46 (90.2)	10 (83.3)	15 (88.2)	0.793
Smoking, n (%)	12 (15.2)	8 (15.7)	1 (8.3)	3 (17.7)	0.767
CAD, n (%)	57 (71.3)	37 (72.6)	8 (66.7)	12 (70.6)	0.919
NYHA class					0.328
NYHA 1, n (%)	7 (8.8)	7 (13.7)	0 (0.0)	0 (0.0)
NYHA 2, n (%)	29 (36.3)	18 (35.3)	4 (33.3)	7 (41.2)
NYHA 3, n (%)	44 (55.0)	26 (51.0)	8 (66.7)	10 (58.8)
Atrial fibrillation, n (%)	80 (100.0)	51 (100.0)	12 (100.0)	17 (100.0)	>0.999
H₂FPEF score	6.0 (5.3–6.0)	6.0 (5.0–7.0)	6.0 (6.0–6.0)	6.0 (5.5–6.0)	0.595
H₂FPEF score ≥6 points	60 (75.0)	37 (72.5)	10 (83.3)	13 (76.5)	0.731
Medication
β-Blocker, n (%)	67 (85.9)	44 (86.3)	10 (83.3)	13 (76.5)	0.637
ACE-I/AT-1 blocker, n (%)	63 (78.8)	42 (82.4)	8 (66.7)	13 (76.5)	0.474
m antagonist, n (%)	15 (18.8)	8 (15.7)	2 (16.7)	5 (29.4)	0.446
Sacubitril/valsartan, n (%)	4 (5.0)	3 (5.9)	0 (0.0)	1 (6.3)	0.690
Diuretic, n (%)	72 (90.0)	47 (92.2)	10 (83.3)	15 (94.1)	0.242
Laboratory markers
Creatinine (mg/dL)	1.1 (0.9–1.5)	1.1 (0.9–1.6)	1.1 (0.9–1.4)	1.2 (0.9–1.7)	0.636
Haemoglobin (mg/dL)	12.7 (11.7–14.0)	12.4 (10.5–14.0)	13.0 (11.9–14.1)	12.6 (9.5–14.2)	0.497
NT-proBNP (ng/mL)	1756 (1034–3340)	1882 (994–3074)	1620 (1020–2608)	1768 (1175–3973)	0.638

BMI, body mass index; CAD, coronary artery disease.

This Feature Is Available To Subscribers Only